Truly resistant patients with advanced renal cell carcinoma receiving first line sunitinib: Analysis of VEGF and VEGFR polymorphisms

被引：0
|
作者：
Bianconi, M. [1 ]
Scartozzi, M. [2 ]
Faloppi, L. [1 ]
Loretelli, C. [1 ]
Zizzi, A. [3 ]
Giampieri, R. [1 ]
Del Prete, M. [1 ]
Burattini, L. [2 ]
Montironi, R. [3 ]
Cascinu, S. [1 ]
机构：
[1] Univ Politecn Marche, Dept Med Oncol, Ancona, Italy
[2] AOU Osped Riuniti, Dept Med Oncol, Ancona, Italy
[3] Univ Politecn Marche, Dept Pathol Anat, Ancona, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2799
引用
收藏
页码：S675 / S675
页数：1
相关论文
共 50 条
  • [1] VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
    Scartozzi, M.
    Bianconi, M.
    Faloppi, L.
    Loretelli, C.
    Bittoni, A.
    Del Prete, M.
    Giampieri, R.
    Maccaroni, E.
    Nicoletti, S.
    Burattini, L.
    Minardi, D.
    Muzzonigro, G.
    Montironi, R.
    Cascinu, S.
    [J]. BRITISH JOURNAL OF CANCER, 2013, 108 (05) : 1126 - 1132
  • [2] VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
    M Scartozzi
    M Bianconi
    L Faloppi
    C Loretelli
    A Bittoni
    M Del Prete
    R Giampieri
    E Maccaroni
    S Nicoletti
    L Burattini
    D Minardi
    G Muzzonigro
    R Montironi
    S Cascinu
    [J]. British Journal of Cancer, 2013, 108 : 1126 - 1132
  • [3] Effect of VEGF and VEGFR polymorphisms on clinical outcome and response in patients with advanced renal cell carcinoma receiving first-line treatment
    Bianconi, Maristella
    Scartozzi, Mario
    Faloppi, Luca
    Loretelli, Cristian
    Zizzi, Antonio
    Giampieri, Riccardo
    Bittoni, Alessandro
    Del Prete, Michela
    Burattini, Luciano
    Montironi, Rodolfo
    Cascinu, Stefano
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [4] TUMOUR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS (VEGFR) POLYMORPHISMS AND CLINICAL OUTCOME IN ADVANCED RENAL CELL CARCINOMA PATIENTS RECEIVING FIRST LINE SUNITINIB
    Bianconi, M.
    Scartozzi, M.
    Faloppi, L.
    Loretelli, C.
    Burattini, L.
    Bittoni, A.
    Del Prete, M.
    Giampieri, R.
    Montironi, R.
    Cascinu, S.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 274 - 274
  • [5] The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptors (VEGFR) polymorphisms in the prediction of clinical outcome for advanced renal cell carcinoma patients receiving first-line sunitinib
    Bianconi, Maristella
    Scartozzi, Mario
    Faloppi, Luca
    Giampieri, Riccardo
    Maccaroni, Elena
    Bittoni, Alessandro
    Del Prete, Michela
    Loretelli, Cristian
    Belvederesi, Laura
    Conti, Alessandro
    Burattini, Luciano
    Minardi, Daniele
    Silva, Rosa Rita
    Montironi, Rodolfo
    Cascinu, Stefano
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) polymorphisms in the prediction of clinical outcome for patients with advanced renal cell carcinoma receiving first-line sunitinib.
    Bianconi, Maristella
    Scartozzi, Mario
    Faloppi, Luca
    Giampieri, Riccardo
    Maccaroni, Elena
    Bittoni, Alessandro
    Del Prete, Michela
    Loretelli, Cristian
    Belvederesi, Laura
    Conti, Alessandro
    Minardi, Daniele
    Burattini, Luciano
    Montironi, Rodolfo
    Cascinu, Stefano
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [7] Effects of VEGF and VEGFR polymorphisms on the outcome of patients with metastatic renal cell carcinoma treated with sunitinib: a systematic review and meta-analysis
    Miao, Chenkui
    Cao, Jingyi
    Wang, Yuhao
    Liu, Bianjiang
    Wang, Zengjun
    [J]. ONCOTARGET, 2017, 8 (40) : 68854 - 68862
  • [8] HEALTH STATE UTILITIES IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA RECEIVING FIRST-LINE PEMBROLIZUMAB PLUS AXITINIB OR SUNITINIB
    Bensimon, A.
    Lai, Y.
    Xu, R.
    Bhattacharya, R.
    Shinde, R.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S554 - S554
  • [9] Dosing schedules and outcomes in patients with first-line sunitinib for advanced renal cell carcinoma
    Kitamura, Hiroshi
    Inoue, Ryuta
    Shindo, Tetsuya
    Nishiyama, Naotaka
    Masumori, Naoya
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 102 - 102
  • [10] Persistence and Compliance Among US Patients Receiving Pazopanib or Sunitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: A Retrospective Claims Analysis
    DaCosta, Stacey A.
    McPheeters, Jeffrey T.
    Burton, Tanya M.
    Nagar, Saurabh P.
    Hackshaw, Michelle D.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2015, 21 (06): : 515 - 522
12345